Vascodagama Online Journal

Uveitis Emerging Drugs and Key Players | DelveInsight

 Breaking News
  • No posts were found

Uveitis Emerging Drugs and Key Players | DelveInsight

August 01
01:04 2020
Uveitis Emerging Drugs and Key Players | DelveInsight

DelveInsight Business Research LLP
Uveitis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Uveitis market. A detailed picture of the Uveitis pipeline landscape is provided, which includes the disease overview and Uveitis treatment guidelines.

Uveitis is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as specific white blood cells rush to the affected part.

Launch of emerging therapies, such as Sirolimus (for Non-Infectious Uveitis of the Posterior Segment (NIU-PS)), EGP-437 (for Non-Infectious Anterior Uveitis), Sarilumab (for Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)), and LME636 ( Anterior Acute Uveitis), shall further create a positive impact on the market.

Sirolimus (Opsiria, Santen) is a macrolide compound derived from Streptomyces hygroscopicus.It has a potent immunosuppressive and antineoplastic activity that depends on its binding to specific cytosolic proteins (immunophilins) to generate an immunosuppressive complex. Sirolimus inhibits the activity of the serine/threonine-protein kinase of the mammalian target of rapamycin (mTOR).

The phase III SAKURA 1 and 2 studies reported significant improvement in reducing ocular inflammation in patients with active noninfectious uveitis and successful tapering of corticosteroid dose (

Iontophoresis is a noninvasive method in which low electrical current is applied to an ionizable substance to increase its mobility across a surface through electrochemical repulsion. Sarilumab is under the development by Sanofi Aventis. The therapeutic candidate is in Phase II stage of development for the treatment of Uveitis. It is also approved for the treatment of Rheumatoid arthritis. The therapeutic candidate acts by binding to the Interleukin-6 Receptor.


The launch of the emerging therapies is expected to significantly impact the Uveitis treatment scenario in the upcoming years:-
Drugs covered
1. ADX-102
2. Sirolimus
And many others

The key players in Uveitis market are:
1. Aldeyra Therapeutics Inc
2. Santen
And many others


Scope of Uveitis Report

  • The Uveitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Uveitis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Uveitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Uveitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Uveitis.


Request for sample pages

Table of contents

1. Report Introduction

2. Uveitis 

2.1. Overview

2.2. History 

2.3. Uveitis Symptoms

2.4. Causes


2.6. Uveitis Diagnosis 

2.6.1. Diagnostic Guidelines

3. Uveitis Current Treatment Patterns

3.1. Uveitis Treatment Guidelines

4. Uveitis – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Uveitis companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Uveitis Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Uveitis Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Uveitis Late Stage Products (Phase-III)

7. Uveitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Uveitis Discontinued Products

13. Uveitis Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report? 

14. Uveitis Key Companies

15. Uveitis Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Uveitis Unmet Needs

18. Uveitis Future Perspectives

19. Uveitis Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States